Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Expert Opinion / Cases · May 22, 2017

Low Risk Oncotype DX Score in a T3 Hormone Receptor Positive Breast Cancer

Written by
Sameer Nasir MD

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • CARLOS MONTENEGRO

    May 26, 2017

    Radiation for chest wall and tamoxifen for 10 years (she can switch on the way)

  • HAMDI Djelloul

    May 26, 2017

    Chest radiation , then tamoxifen for 5 years. 

  • Andrea de Matteis

    May 28, 2017

    No Radiotherapy. If the patient is premenopausal Tamoxifen. After 5 years if postmenopausal Letrozole x 5 years.

  • Waseem Abbas

    Jun 05, 2017

    Young patient with a pT3 tumor definitely chemotherapy followed by radiation and ovarian ablation plus Letrazole. If she is not willing then only we can avoid chemotherapy.

  • CARLOS MONTENEGRO

    Jun 19, 2017

    Since she has done Oncotype with a low  risk result we could avoid CHEMO

  • Bharat Bhosale

    Jul 25, 2017

    No chemo
    Grade 2 
    Ki 67 15 % 
    Strong ER PR positive
    Low RS
    I would treat with radiation and 5 to 10 years of tamoxifen 

  • ibra algo

    Jul 26, 2017

    Young age ( 43-ys ) + T3 > 5 cm = yes for Radiation therapy. ONCdx < 11 , (TAILORx). limited for Tumor =<5 cm. this patient > 5 cm . So need to have adjuvant chemotherapy but without anthracycline, since she is LN -VE ER PR +ve (SEE Blum 2017 JCO The ABC TRIALS Anthracyclines in Early Breast Cancer)

  • Kavi Capildeo

    Jul 26, 2017

    Agree with above commenters that chemotherapy would not be indicated in this patient with Stage IIB node negative, ER and PR positive breast cancer with a low Oncotype.
    Multiple valid options for endocrine therapy including initial Tamoxifen with possible crossover to Letrozole if postmenopausal at 5 yrs as per MA-17, vs. exemestane + ovarian suppression as per SOFT/TEXT.
    Postmastectomy RT to chest wall is indicated in view of T3 tumor. 

  • Juan Rodriguez Agostini

    Jul 27, 2017

    1.- Postmastectomy radiation therapy by tumor size
    2.- Only adjuvant hormone therapy + ovarian supression

  • ANTHONY PAIS

    Aug 09, 2017

    43 years premenopausal women, ER positive, low KI67. Risk score is low. Nodes negative. Mastectomy done. Would advise only Tamoxifen +/- oophorectomy after discussing with the patient.

  • thomas tucker

    Aug 09, 2017

    XRT plus tamoxifen

  • Waseem Abbas

    Aug 10, 2017

    Do we have a randomized data .???Chemotherapy vs no chemotherapy in early breast cancer. Oncotype DS is the retrospective data . And other scores have no comparative arm as chemotherapy,Evidence based medicine..... 

  • Shahid Gilani

    Aug 14, 2017

    Post mastectomy Radiation therapy to chest wall. Ovarian suppression with endocrine treatment for 10 years (AI for 5 years +Tamoxifin for 5 years). 

  • Apr 24, 2024

    Pending Moderator approval.
    Delete

Further Reading